{"gene":"DUSP3","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1994,"finding":"Cys124 is the catalytic nucleophile of VHR/DUSP3: the C124S mutation abolishes both Tyr and Thr/Ser phosphatase activities, a thiol-phosphate enzyme intermediate forms at Cys124 during catalysis, and Cys124 is specifically alkylated by iodoacetate, establishing a mechanism identical to that of tyrosine-specific PTPs.","method":"Active-site mutagenesis (C124S), 32P-labeling of phosphoenzyme intermediate, iodoacetate alkylation, in vitro phosphatase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in vitro with mutagenesis and chemical modification, multiple orthogonal methods in a single rigorous study","pmids":["7961745"],"is_preprint":false},{"year":1995,"finding":"Pre-steady-state burst kinetics demonstrate that VHR/DUSP3 catalysis proceeds through a phosphoenzyme intermediate, and the rate-limiting step is decomposition of this intermediate (dephosphorylation), not the initial phosphoryl transfer from substrate to Cys124.","method":"Pre-steady-state burst kinetic analysis with p-nitrophenyl phosphate; linear free-energy relationship analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinetic reconstitution with rigorous mechanistic analysis","pmids":["8519766"],"is_preprint":false},{"year":1996,"finding":"Crystal structure of VHR/DUSP3 at 2.1 Å resolution reveals a shallow active-site pocket (explaining dual-specificity toward pSer/pThr/pTyr) compared to the deeper pocket of tyrosine-specific PTPs, positively charged crevices near the active site, and a 'recognition region' (helix α1 to strand β1) that likely determines substrate specificity differences among DSPs and PTPs.","method":"X-ray crystallography at 2.1 Å resolution","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure, foundational structural study replicated and extended by subsequent work","pmids":["8650541"],"is_preprint":false},{"year":1996,"finding":"Kinetic isotope effect measurements show VHR/DUSP3 employs a highly dissociative transition state for phosphoryl transfer (similar to uncatalyzed reaction and other PTPs), with Asp92 acting as general acid to protonate the leaving group; D92N mutant loses general acid assistance; S131A mutation raises the pKa of the nucleophilic Cys but does not alter transition-state structure.","method":"Kinetic isotope effects (18O nonbridge, 18O bridge, 15N) measured by isotope ratio mass spectrometry; site-directed mutagenesis (D92N, S131A, D92N/S131A)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous mechanistic in vitro study with multiple mutants and isotope effect measurements","pmids":["8679534"],"is_preprint":false},{"year":1999,"finding":"ERK1 and ERK2 are authentic substrates of VHR/DUSP3: VHR specifically dephosphorylates and inactivates ERK1/2 in vitro and in vivo (but not p38 or JNK in this study), with a second-order rate constant of ~40,000 M⁻¹s⁻¹; immunodepletion of endogenous VHR eliminates cellular ERK dephosphorylation; VHR is constitutively expressed and nuclear.","method":"Covalently immobilized mutant VHR affinity trap, kinetic in vitro phosphatase assay, transfection in COS-1 cells, immunodepletion","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate trap affinity enrichment + in vitro kinetics + cell-based immunodepletion, multiple orthogonal methods","pmids":["10224087"],"is_preprint":false},{"year":2000,"finding":"Introduction of exogenous VHR into Jurkat T cells suppresses TCR-induced activation of ERK1/2 and JNK1/2 (and NFAT/AP-1 and Elk/c-Jun-driven reporters), but not p38 or NF-κB; catalytically inactive VHR mutants cause increased gene activation, indicating that endogenous VHR tonically suppresses the ERK and JNK pathways in T cells.","method":"Transfection of wild-type and catalytically inactive VHR in Jurkat T cells; luciferase reporter assays; kinase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function (dominant-negative) and gain-of-function with multiple pathway readouts replicated across reporters","pmids":["11085983"],"is_preprint":false},{"year":2000,"finding":"Cu²⁺ ions potently and reversibly inactivate VHR/DUSP3 at submicromolar concentrations by oxidizing the active-site Cys124, as shown by loss of [¹⁴C]iodoacetate labeling of that residue; the reduction potential of VHR is estimated at −331 mV. Zn²⁺ inactivates VHR through a distinct mechanism not involving active-site Cys124.","method":"In vitro phosphatase activity assay with metal ions; [¹⁴C]iodoacetate active-site labeling; DTT reversal; Y78F mutant comparison","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro biochemical study with multiple methods but single lab, not independently replicated","pmids":["11051099"],"is_preprint":false},{"year":2002,"finding":"Crystal structure at 2.75 Å of catalytically inactive C124S VHR in complex with a bisphosphorylated MAP kinase activation-loop peptide reveals that phosphotyrosine occupies the deep active-site cleft while phosphothreonine is tethered in a nearby basic pocket containing Arg158, explaining VHR's strong preference for dephosphorylating pTyr over pThr within bisphosphorylated -pTXpY- substrates.","method":"X-ray crystallography of C124S VHR–bisphosphorylated peptide complex at 2.75 Å; biochemical dephosphorylation assays; mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — first substrate-bound DSP crystal structure with biochemical validation of key residues","pmids":["11863439"],"is_preprint":false},{"year":2002,"finding":"VHR/DUSP3 efficiently dephosphorylates and inactivates JNK; the catalytically inactive C124S VHR forms a tight complex with activated JNK in vivo (substrate trap); c-Jun inhibits VHR-mediated JNK dephosphorylation in vitro by sterically blocking phosphorylation-site access when JNK and c-Jun are complexed, but c-Jun does not affect VHR activity toward ERK or artificial substrates.","method":"In vitro phosphatase assay, C124S substrate trap in vivo, c-Jun inhibition assay in vitro","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate trap plus in vitro kinetics plus mechanistic inhibition study, multiple methods in one lab","pmids":["11971192"],"is_preprint":false},{"year":2002,"finding":"VHR/DUSP3 is phosphorylated at Tyr138 by the ZAP-70 tyrosine kinase following TCR stimulation; Tyr138 phosphorylation is required for VHR to inhibit the ERK2-Elk-1 pathway, and the VHR(Y138F) mutant augments TCR-induced ERK2 activity and IL-2 gene activation.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Y138F), transfection/reporter assay in T cells","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — writer kinase identified, phosphosite mutant with functional readout, multiple orthogonal methods","pmids":["12447358"],"is_preprint":false},{"year":2006,"finding":"RNAi-mediated loss of VHR/DUSP3 causes cell-cycle arrest at G1/S and G2/M transitions, senescence markers (β-galactosidase staining, autophagosomes, p21Cip/Waf1 upregulation, decreased telomerase), and hyperactivation of JNK and ERK; the cell-cycle arrest is reversed by JNK and ERK inhibition or knockdown, placing VHR upstream of these MAP kinases in cell-cycle regulation.","method":"RNAi knockdown, cell-cycle analysis, senescence assays (β-gal, autophagosome), kinase activity assays, JNK/ERK inhibitor rescue","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via inhibitor/siRNA rescue, multiple phenotypic readouts, replicated approach","pmids":["16604064"],"is_preprint":false},{"year":2006,"finding":"VRK3 kinase binds directly to VHR/DUSP3 and enhances its phosphatase activity toward ERK in the nucleus through a mechanism independent of VRK3 kinase activity, thereby suppressing ERK signaling; VRK3 defines a class of 'phosphatase-activating kinases'.","method":"Co-immunoprecipitation, in vitro phosphatase activity assay with VRK3, VRK3 kinase-dead mutant, nuclear co-localization studies","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding shown by Co-IP, activity enhancement confirmed in vitro with kinase-dead mutant ruling out indirect phosphorylation","pmids":["16845380"],"is_preprint":false},{"year":2007,"finding":"VHR/DUSP3 selectively dephosphorylates IFN-α/β-activated, tyrosine-phosphorylated STAT5 in the nucleus, inhibiting STAT5 transcriptional activity; Tyr138 phosphorylation of VHR is required for its phosphatase activity toward STAT5; the Src homology 2 (SH2) domain of STAT5 is required for effective dephosphorylation by VHR; Tyk2 kinase phosphorylates VHR at Tyr138.","method":"Phosphatase assay, co-immunoprecipitation, VHR Y138F mutant, STAT5 SH2-domain mutant analysis, reporter assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — new substrate identified, phosphosite requirement established, reader domain requirement on substrate identified, writer kinase named, multiple orthogonal methods","pmids":["17785772"],"is_preprint":false},{"year":2008,"finding":"VHR/DUSP3 localizes to the cytoplasm in primary keratinocytes but relocates to both cytoplasm and nucleus in cervical cancer cell lines; this relocalization correlates with post-translational stabilization of VHR protein (not increased DUSP3 transcription) in cancer cells.","method":"Immunofluorescence/confocal microscopy, Western blotting, RT-PCR","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment with functional implication (post-translational stabilization), two methods, single lab","pmids":["18505570"],"is_preprint":false},{"year":2013,"finding":"GST-DUSP3 pulldown from HeLa cells exposed to gamma/UV radiation followed by LC-MS/MS identified Nucleophosmin (NPM), HnRNP C1/C2, and Nucleolin as direct DUSP3-interacting proteins; these interactions were validated by co-immunoprecipitation.","method":"GST pulldown, LC-MS/MS proteomics, co-immunoprecipitation validation","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pulldown with MS identification plus reciprocal Co-IP, single lab","pmids":["24245651"],"is_preprint":false},{"year":2013,"finding":"Systematic combinatorial peptide library profiling reveals VHR/DUSP3 recognizes two distinct classes of phosphotyrosine peptide substrates: Class I ((D/E/ϕ)(D/S/N/T/E)(P/I/M/S/A/V)pY(G/A/S/Q)) binding in canonical orientation, and Class II ((V/A)P(I/L/M/V/F)Xn pY) binding in an inverted orientation where the N-terminus interacts with Asp164; this alternative binding mode was supported by site-directed mutagenesis and molecular modeling.","method":"Combinatorial peptide library screening, site-directed mutagenesis, molecular modeling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro substrate specificity reconstitution with mutagenesis, single lab but comprehensive systematic approach","pmids":["23322772"],"is_preprint":false},{"year":2014,"finding":"VHR/DUSP3 can homodimerize inside cells; photo-cross-linking (pBPA amber suppression) and chemical cross-linkers identified Phe68 as a residue involved in dimerization; dimerization reduces VHR catalytic activity, suggesting the dimer interface occludes the active site as a negative regulatory mechanism.","method":"Unnatural amino acid (pBPA) photo-cross-linking, chemical cross-linking, in vitro phosphatase activity assay of dimeric vs monomeric VHR","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — novel method (amber suppression cross-linking) plus chemical cross-linking plus activity assay, single lab but multiple orthogonal approaches","pmids":["24798147"],"is_preprint":false},{"year":2014,"finding":"DUSP3 deficiency in mice reduces neo-vascularization (b-FGF Matrigel plug, LLC tumor xenograft, aortic ring assay); DUSP3 knockdown in human endothelial cells reduces tube formation and spheroid sprouting, associated with increased PKC phosphorylation (not altered ERK1/2, JNK1/2, or EGFR phosphorylation in this context), identifying DUSP3 as a pro-angiogenic phosphatase.","method":"DUSP3-knockout mice (homologous recombination), RNAi in endothelial cells, Matrigel tube formation, aortic ring assay, phosphoprotein analysis","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mice plus in vitro RNAi with multiple angiogenesis assays, mechanistic link to PKC pathway identified","pmids":["24886454"],"is_preprint":false},{"year":2015,"finding":"DUSP3 deficiency in mice promotes tolerance to LPS-induced endotoxin shock and polymicrobial septic shock; this is macrophage-dependent and transferable by adoptive transfer; DUSP3-/- mice show increased M2-like macrophages, decreased TNF production, and impaired ERK1/2 activation, demonstrating DUSP3 regulates innate immune responses through ERK1/2 and macrophage polarization.","method":"DUSP3-/- mice, LPS/CLP models, adoptive bone-marrow transfer, FACS macrophage phenotyping, ERK1/2 phosphorylation assay, ELISA for TNF","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with adoptive transfer (mechanistic proof of macrophage dependence), multiple readouts","pmids":["25876765"],"is_preprint":false},{"year":2016,"finding":"Nuclear HSP70 enhances VHR/DUSP3 phosphatase activity via direct protein–protein interaction (not chaperone activity); VRK3 facilitates nuclear localization of HSP70; this VRK3/HSP70/VHR axis suppresses excessive ERK activation following glutamate excitotoxicity and reduces apoptosis and Aβ accumulation.","method":"Co-immunoprecipitation, in vitro phosphatase activity assay, nuclear localization signal-fused HSP70 overexpression, VRK3-deficient neurons, VRK3/HSP70 knockdown","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP binding plus direct phosphatase activity assay, single lab, two orthogonal methods","pmids":["27941812"],"is_preprint":false},{"year":2016,"finding":"Loss of Dusp3/VHR by RNAi in human mitotic cancer cells causes multipolar spindle formation in an ERK1/2-dependent manner; normal bipolar spindle structure is restored by chemical inhibition of ERK1/2 or ectopic Dusp3 overexpression, placing Dusp3 upstream of ERK1/2 in mitotic spindle regulation.","method":"RNAi knockdown, ERK1/2 inhibitor rescue, Dusp3 overexpression rescue, spindle morphology analysis by microscopy","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis by inhibitor and overexpression rescue, single lab, clear phenotypic readout","pmids":["27423135"],"is_preprint":false},{"year":2017,"finding":"VHR/DUSP3 directly dephosphorylates FAK (focal adhesion kinase) and paxillin in vitro; VHR overexpression decreases FAK tyrosine phosphorylation and VHR deficiency increases it; VHR-knockout cells show stronger FAK and paxillin phosphorylation, higher EGFR phosphorylation, long-lasting trailing ends, slower focal adhesion turnover, and elevated cell migration, identifying VHR as a FAK phosphatase regulating focal adhesion dynamics.","method":"Co-immunoprecipitation, in vitro phosphatase assay with recombinant VHR and FAK, VHR-knockout mouse-derived cells, VHR overexpression, focal adhesion microscopy","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted phosphatase assay plus KO cells plus overexpression with multiple functional readouts, single lab but rigorous","pmids":["28759036"],"is_preprint":false},{"year":2020,"finding":"Allosteric communication exists between the variable insert region (residue Asn74) and the catalytic acid loop of VHR/DUSP3: N74A mutation rigidifies the acid loop (NMR and MD simulations), disrupts active-site hydrogen bonds, weakens substrate affinity, and reduces substrate cleavage and hydrolysis rates >2-fold, despite the variable insert being ~20 Å from the active site.","method":"Solution NMR, molecular dynamics simulations, steady-state and rapid kinetic measurements, N74A site-directed mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR + computation + enzyme kinetics with mutagenesis in a single rigorous study, single lab","pmids":["32348128"],"is_preprint":false},{"year":2021,"finding":"DUSP3 directly dephosphorylates Nucleophosmin (NPM) at tyrosines Y29, Y67, and Y271 after UV-radiation stress; DUSP3 knockdown causes early nucleolus exit of NPM and ARF, disruption of the HDM2-p53 interaction, increased p53-Ser15 phosphorylation, prolonged p53 half-life, and enhanced p53 transcriptional activity, demonstrating that DUSP3-mediated NPM dephosphorylation fine-tunes p53 signaling to maintain genomic stability.","method":"Co-immunoprecipitation, phospho-specific antibodies to individual NPM Tyr residues, in vitro phosphatase assay, DUSP3 siRNA knockdown, p53 stability/transcription assays","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct dephosphorylation assay plus site-specific phospho-antibodies plus KD with p53 pathway readouts, multiple orthogonal methods, single lab","pmids":["33777934"],"is_preprint":false},{"year":2022,"finding":"DUSP3 directly dephosphorylates occludin (OCLN) tyrosine residues; DUSP3 deficiency increases OCLN tyrosine phosphorylation, OCLN ubiquitination, and OCLN degradation, leading to disrupted tight junction ZO-1 distribution and impaired epithelial barrier function; DUSP3 also suppresses OCLN kinase FAK to reduce OCLN phosphorylation indirectly.","method":"Proximity ligation assay, immunoblotting, in vitro phosphatase assay, DUSP3-deficient cells, OCLN Tyr-to-Ala mutants, ubiquitination assay","journal":"Journal of biomedical science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphatase reconstitution plus site-directed mutagenesis of substrate Tyr residues plus PLA and functional barrier assay, single lab","pmids":["35705979"],"is_preprint":false},{"year":2024,"finding":"DUSP3 dephosphorylates HnRNP C (HNRNPC) tyrosine residues; DUSP3 knockdown causes tyrosine hyperphosphorylation of HNRNPC, increasing its RNA-binding ability and its association with IRES trans-acting factor (ITAF) complexes, leading to enhanced IRES-dependent translation of c-MYC and XIAP mRNAs. DUSP3 is present in 40S, monosome, and polysome fractions interacting with HNRNPC, PABP, and Nucleolin.","method":"DUSP3 siRNA knockdown, tyrosine phospho-HNRNPC immunoblotting, RNA immunoprecipitation, polysome fractionation, qPCR for mRNA levels vs protein levels","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple methods but single lab, no in vitro reconstitution of HNRNPC dephosphorylation by DUSP3","pmids":["38538536"],"is_preprint":false},{"year":2025,"finding":"Fragment-based screening using fluorine NMR identified novel ligand-binding sites on VHR/DUSP3 distant from the conserved active site (allosteric sites); crystal structures confirmed fragment–protein interactions at these novel sites, providing structural basis for allosteric modulation.","method":"Fluorine NMR fragment screening, X-ray crystallography of fragment-bound VHR","journal":"ACS omega","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structures confirm binding sites but functional/activity consequences of allosteric site occupancy not fully characterized in abstracts reviewed","pmids":["39959108"],"is_preprint":false}],"current_model":"DUSP3/VHR is a small, nuclear dual-specificity phosphatase that uses an active-site Cys124 thiol-phosphate intermediate (with Asp92 as general acid) to dephosphorylate phosphotyrosine preferentially within bisphosphorylated -pTXpY- motifs; its established substrates include ERK1/2, JNK1/2, STAT5 (after Tyk2-mediated VHR-pY138 activation), FAK, paxillin, nucleophosmin (Y29/Y67/Y271), occludin, and HnRNP C, placing DUSP3 as a constitutive brake on MAP kinase signaling that is itself regulated by ZAP-70/Tyk2-mediated Tyr138 phosphorylation, by VRK3-mediated allosteric activation (enhanced by nuclear HSP70), and by homodimerization-induced active-site occlusion; loss of DUSP3 causes G1/S and G2/M cell-cycle arrest, senescence, multipolar mitotic spindles, defective focal adhesion turnover, impaired angiogenesis, and altered innate immune macrophage polarization, while its nuclear dephosphorylation of NPM fine-tunes p53 stability and DNA-damage responses."},"narrative":{"mechanistic_narrative":"DUSP3 (VHR) is a constitutively expressed dual-specificity phosphatase that acts as a tonic brake on tyrosine-phosphorylation signaling, particularly within the MAP kinase pathways [PMID:10224087, PMID:11085983, PMID:16604064]. Catalysis proceeds through a classical cysteine-based phosphatase mechanism: Cys124 is the nucleophile that forms a covalent thiol-phosphate intermediate, Asp92 serves as the general acid protonating the leaving group, and the rate-limiting step is decomposition of the phosphoenzyme intermediate via a highly dissociative transition state [PMID:7961745, PMID:8519766, PMID:8679534]. A shallow active-site pocket accommodates pSer/pThr/pTyr, but structural and peptide-library analyses show a strong preference for dephosphorylating phosphotyrosine within bisphosphorylated -pTXpY- motifs, with phosphotyrosine occupying the deep catalytic cleft and phosphothreonine tethered in an adjacent basic pocket [PMID:8650541, PMID:11863439, PMID:23322772]. Through this activity DUSP3 dephosphorylates and inactivates ERK1/2 and JNK1/2, and these substrates define its role in cell-cycle progression: loss of DUSP3 hyperactivates ERK and JNK, causing G1/S and G2/M arrest, senescence, and ERK-dependent multipolar mitotic spindles [PMID:10224087, PMID:11971192, PMID:16604064, PMID:27423135]. The enzyme is itself regulated on multiple axes — activating Tyr138 phosphorylation by ZAP-70 and Tyk2 (required for activity toward the ERK–Elk-1 pathway and STAT5) [PMID:12447358, PMID:17785772], allosteric activation by VRK3 binding that is enhanced by nuclear HSP70 [PMID:16845380, PMID:27941812], and negative regulation by homodimerization that occludes the active site [PMID:24798147]. Beyond MAP kinases, DUSP3 dephosphorylates a defined set of substrates including STAT5 [PMID:17785772], FAK and paxillin to control focal adhesion turnover and migration [PMID:28759036], occludin to maintain tight-junction barrier integrity [PMID:35705979], nucleophosmin (Y29/Y67/Y271) to fine-tune p53 stability and DNA-damage responses [PMID:33777934], and HnRNP C to regulate IRES-dependent translation of c-MYC and XIAP [PMID:38538536]. At the organismal level DUSP3 is pro-angiogenic [PMID:24886454] and shapes innate immune responses, where its deficiency confers tolerance to endotoxin/septic shock through macrophage-dependent ERK1/2 regulation and M2 polarization [PMID:25876765].","teleology":[{"year":1994,"claim":"Established the catalytic mechanism of VHR/DUSP3 by identifying Cys124 as the nucleophile, resolving how a dual-specificity phosphatase achieves both pTyr and pSer/pThr hydrolysis.","evidence":"C124S mutagenesis, 32P phosphoenzyme intermediate trapping, iodoacetate alkylation, in vitro assay","pmids":["7961745"],"confidence":"High","gaps":["Did not identify physiological substrates","Subcellular context and regulation unaddressed"]},{"year":1995,"claim":"Defined the kinetic pathway, showing the rate-limiting step is breakdown of the phosphoenzyme intermediate rather than initial phosphoryl transfer.","evidence":"Pre-steady-state burst kinetics with pNPP, linear free-energy analysis","pmids":["8519766"],"confidence":"High","gaps":["Used artificial substrate only","No physiological substrate kinetics"]},{"year":1996,"claim":"Provided the structural basis for dual specificity and substrate recognition through the first crystal structure and transition-state/general-acid analysis.","evidence":"X-ray crystallography at 2.1 Å; kinetic isotope effects with D92N/S131A mutagenesis","pmids":["8650541","8679534"],"confidence":"High","gaps":["No substrate-bound complex","Specificity determinants for cellular substrates not validated"]},{"year":1999,"claim":"Identified ERK1/2 as authentic cellular substrates, defining DUSP3 as a constitutive nuclear brake on MAP kinase signaling.","evidence":"Substrate-trap affinity enrichment, in vitro kinetics, immunodepletion in COS-1 cells","pmids":["10224087"],"confidence":"High","gaps":["JNK/p38 selectivity context-dependent","Recruitment to substrates not defined"]},{"year":2000,"claim":"Demonstrated DUSP3 tonically suppresses ERK and JNK in T cells, and that the active-site Cys is redox-sensitive, linking enzyme activity to signaling and metal-mediated regulation.","evidence":"WT/catalytically dead VHR in Jurkat cells with reporters; Cu2+/Zn2+ inactivation with iodoacetate labeling","pmids":["11085983","11051099"],"confidence":"High","gaps":["Physiological relevance of metal inactivation in vivo unestablished","p38/NF-κB exclusion may be cell-type specific"]},{"year":2002,"claim":"Resolved substrate recognition and activating regulation: a substrate-bound structure explained pTyr preference within -pTXpY- motifs, JNK was confirmed as substrate, and ZAP-70-mediated Tyr138 phosphorylation was shown to be required for activity.","evidence":"C124S–bisphosphopeptide crystal structure; JNK substrate trap with c-Jun inhibition; Co-IP/kinase assay/Y138F mutant in T cells","pmids":["11863439","11971192","12447358"],"confidence":"High","gaps":["Structural basis of Tyr138-dependent activation not solved","Whether c-Jun occlusion operates in vivo unclear"]},{"year":2006,"claim":"Placed DUSP3 upstream of ERK/JNK in cell-cycle control and identified VRK3 as a kinase-independent allosteric activator, revealing both phenotypic consequence and a novel activation mechanism.","evidence":"RNAi with senescence/cell-cycle assays and JNK/ERK inhibitor rescue; Co-IP and in vitro activity assay with VRK3 kinase-dead mutant","pmids":["16604064","16845380"],"confidence":"High","gaps":["Molecular mechanism of VRK3 allosteric activation undefined","Direct cell-cycle substrate beyond ERK/JNK not identified"]},{"year":2007,"claim":"Extended substrate range to interferon-activated STAT5 and confirmed Tyk2-mediated Tyr138 phosphorylation as a requirement for activity, integrating DUSP3 into cytokine signaling.","evidence":"Phosphatase assay, Co-IP, VHR Y138F and STAT5 SH2-domain mutants, reporter assays","pmids":["17785772"],"confidence":"High","gaps":["In vivo relevance to IFN responses not tested","Mechanism of SH2-dependent recognition not structurally defined"]},{"year":2008,"claim":"Linked DUSP3 subcellular distribution to cancer, showing nuclear relocalization and post-translational stabilization in cervical cancer cells.","evidence":"Immunofluorescence, Western blot, RT-PCR in keratinocytes vs cancer lines","pmids":["18505570"],"confidence":"Medium","gaps":["Mechanism of stabilization unknown","Functional consequence of nuclear shift not directly tested"]},{"year":2013,"claim":"Identified the DNA-damage-induced interactome (NPM, HnRNP C1/C2, Nucleolin) and systematically mapped two substrate-peptide binding classes, broadening DUSP3 substrate logic beyond MAP kinases.","evidence":"GST pulldown with LC-MS/MS and Co-IP validation; combinatorial peptide library with mutagenesis and modeling","pmids":["24245651","23322772"],"confidence":"Medium","gaps":["Pulldown interactions not yet shown to be catalytic substrates in 2013","Class II inverted binding mode based partly on modeling"]},{"year":2014,"claim":"Used knockout mice to establish DUSP3 as pro-angiogenic and to identify a PKC-linked, ERK-independent vascular function, demonstrating non-MAPK signaling roles in vivo.","evidence":"DUSP3-knockout mice, endothelial RNAi, Matrigel/aortic-ring/tube-formation assays, phosphoprotein analysis","pmids":["24886454"],"confidence":"High","gaps":["Direct PKC-pathway substrate not identified","Mechanism connecting DUSP3 to angiogenesis incomplete"]},{"year":2014,"claim":"Revealed homodimerization as a negative autoregulatory mechanism that occludes the active site, adding a layer of intrinsic activity control.","evidence":"pBPA photo-cross-linking and chemical cross-linking identifying Phe68; activity assay of dimer vs monomer","pmids":["24798147"],"confidence":"High","gaps":["Cellular triggers governing monomer/dimer equilibrium unknown","No structure of the dimer interface"]},{"year":2015,"claim":"Defined DUSP3 as an innate-immune regulator, showing macrophage-dependent control of endotoxin/septic shock tolerance through ERK1/2 and M2 polarization.","evidence":"DUSP3-/- mice in LPS/CLP models, adoptive bone-marrow transfer, FACS, ERK1/2 and TNF readouts","pmids":["25876765"],"confidence":"High","gaps":["Direct macrophage substrate beyond ERK pathway not pinned down","Transcriptional drivers of M2 skewing unresolved"]},{"year":2016,"claim":"Connected DUSP3 to mitotic fidelity and to a neuronal protective axis: ERK-dependent control of spindle bipolarity and HSP70-enhanced phosphatase activity downstream of VRK3.","evidence":"RNAi with ERK-inhibitor/overexpression rescue and spindle imaging; Co-IP, activity assay, NLS-HSP70 overexpression in neurons","pmids":["27423135","27941812"],"confidence":"Medium","gaps":["HSP70 activation mechanism (non-chaperone) not structurally defined","Spindle phenotype substrate(s) beyond ERK unclear"]},{"year":2017,"claim":"Identified FAK and paxillin as direct substrates, establishing DUSP3 control of focal adhesion turnover and cell migration.","evidence":"Co-IP, in vitro phosphatase assay with recombinant FAK, knockout cells, overexpression, focal adhesion microscopy","pmids":["28759036"],"confidence":"High","gaps":["Spatial regulation of cytoplasmic DUSP3 at adhesions not defined","Interplay with EGFR signaling not fully resolved"]},{"year":2020,"claim":"Demonstrated long-range allosteric communication from the variable insert (Asn74) to the catalytic acid loop, revealing a structural route for activity modulation distant from the active site.","evidence":"Solution NMR, MD simulations, steady-state/rapid kinetics with N74A mutagenesis","pmids":["32348128"],"confidence":"High","gaps":["Physiological ligand or modifier engaging this allosteric route unknown","Link to VRK3/HSP70 activation not established"]},{"year":2021,"claim":"Showed DUSP3 dephosphorylates NPM at three specific tyrosines to fine-tune p53 stability and the DNA-damage response, converting an earlier interactome hit into a defined catalytic substrate.","evidence":"Co-IP, site-specific phospho-antibodies, in vitro phosphatase assay, siRNA, p53 stability/transcription assays","pmids":["33777934"],"confidence":"High","gaps":["Whether NPM dephosphorylation requires VHR Tyr138 activation untested","Nucleolar dynamics regulation mechanism incomplete"]},{"year":2022,"claim":"Identified occludin as a direct substrate, linking DUSP3 to tight-junction stability and epithelial barrier function via both direct OCLN dephosphorylation and indirect FAK suppression.","evidence":"Proximity ligation assay, in vitro phosphatase assay, OCLN Tyr-to-Ala mutants, ubiquitination and barrier assays in deficient cells","pmids":["35705979"],"confidence":"High","gaps":["In vivo epithelial relevance not tested","Which OCLN tyrosines are primary remains to be ranked"]},{"year":2024,"claim":"Extended DUSP3 function to translational control, showing dephosphorylation of HnRNP C regulates IRES-dependent translation of c-MYC and XIAP and placing DUSP3 in ribosomal fractions.","evidence":"siRNA, phospho-HNRNPC immunoblot, RNA-IP, polysome fractionation, qPCR vs protein","pmids":["38538536"],"confidence":"Medium","gaps":["No in vitro reconstitution of HNRNPC dephosphorylation by DUSP3","Direct vs indirect effect on translation not fully separated"]},{"year":2025,"claim":"Mapped novel allosteric ligand-binding pockets distinct from the catalytic site, providing a structural foundation for allosteric modulators.","evidence":"Fluorine NMR fragment screening with X-ray crystallography of fragment-bound VHR","pmids":["39959108"],"confidence":"Medium","gaps":["Functional consequence of occupying these sites not demonstrated","No lead compound with cellular activity"]},{"year":null,"claim":"How DUSP3's many regulatory inputs (Tyr138 phosphorylation, VRK3/HSP70 binding, dimerization, allosteric insert dynamics) are integrated to select among its diverse substrates in different compartments and cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of substrate selection","Compartment-specific regulation incompletely mapped","Disease-relevant substrate priorities not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,8,12,21,23,24]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,10,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,11,12,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13,21]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[23]},{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,8,12]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18]}],"complexes":[],"partners":["ERK1/2","JNK","STAT5","VRK3","FAK","NPM1","HNRNPC","HSP70"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51452","full_name":"Dual specificity protein phosphatase 3","aliases":["Dual specificity protein phosphatase VHR","Vaccinia H1-related phosphatase","VHR"],"length_aa":185,"mass_kda":20.5,"function":"Shows activity both for tyrosine-protein phosphate and serine-protein phosphate, but displays a strong preference toward phosphotyrosines (PubMed:10224087, PubMed:11863439). Specifically dephosphorylates and inactivates ERK1 and ERK2 (PubMed:10224087, PubMed:11863439)","subcellular_location":"Nucleus; Cytoplasm, cytoskeleton, flagellum axoneme","url":"https://www.uniprot.org/uniprotkb/P51452/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DUSP3","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DUSP3","total_profiled":1310},"omim":[{"mim_id":"619771","title":"VRK SERINE/THREONINE KINASE 3; VRK3","url":"https://www.omim.org/entry/619771"},{"mim_id":"618574","title":"DUAL-SPECIFICITY PHOSPHATASE 29; DUSP29","url":"https://www.omim.org/entry/618574"},{"mim_id":"618368","title":"DUAL-SPECIFICITY PHOSPHATASE 26; DUSP26","url":"https://www.omim.org/entry/618368"},{"mim_id":"616778","title":"DUAL-SPECIFICITY PHOSPHATASE 22; DUSP22","url":"https://www.omim.org/entry/616778"},{"mim_id":"615814","title":"SERINE/THREONINE/TYROSINE-INTERACTING PROTEIN; STYX","url":"https://www.omim.org/entry/615814"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":245.3}],"url":"https://www.proteinatlas.org/search/DUSP3"},"hgnc":{"alias_symbol":[],"prev_symbol":["VHR"]},"alphafold":{"accession":"P51452","domains":[{"cath_id":"3.90.190.10","chopping":"8-179","consensus_level":"medium","plddt":97.5165,"start":8,"end":179}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51452","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51452-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51452-F1-predicted_aligned_error_v6.png","plddt_mean":95.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DUSP3","jax_strain_url":"https://www.jax.org/strain/search?query=DUSP3"},"sequence":{"accession":"P51452","fasta_url":"https://rest.uniprot.org/uniprotkb/P51452.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51452/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51452"}},"corpus_meta":[{"pmid":"8650541","id":"PMC_8650541","title":"Crystal structure of the dual specificity protein phosphatase VHR.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8650541","citation_count":294,"is_preprint":false},{"pmid":"10224087","id":"PMC_10224087","title":"Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224087","citation_count":142,"is_preprint":false},{"pmid":"11085983","id":"PMC_11085983","title":"Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11085983","citation_count":126,"is_preprint":false},{"pmid":"7961745","id":"PMC_7961745","title":"The catalytic role of Cys124 in the dual specificity phosphatase VHR.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7961745","citation_count":107,"is_preprint":false},{"pmid":"16604064","id":"PMC_16604064","title":"Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16604064","citation_count":106,"is_preprint":false},{"pmid":"11051099","id":"PMC_11051099","title":"Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2+ ion.","date":"2000","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/11051099","citation_count":90,"is_preprint":false},{"pmid":"12447358","id":"PMC_12447358","title":"Tyrosine phosphorylation of VHR phosphatase by ZAP-70.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12447358","citation_count":82,"is_preprint":false},{"pmid":"11863439","id":"PMC_11863439","title":"Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11863439","citation_count":78,"is_preprint":false},{"pmid":"11733513","id":"PMC_11733513","title":"Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR).","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11733513","citation_count":69,"is_preprint":false},{"pmid":"16845380","id":"PMC_16845380","title":"Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16845380","citation_count":69,"is_preprint":false},{"pmid":"11563920","id":"PMC_11563920","title":"Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition.","date":"2001","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11563920","citation_count":66,"is_preprint":false},{"pmid":"8679534","id":"PMC_8679534","title":"Transition-state structures for the native dual-specific phosphatase VHR and D92N and S131A mutants. Contributions to the driving force for catalysis.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8679534","citation_count":57,"is_preprint":false},{"pmid":"11971192","id":"PMC_11971192","title":"Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK).","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11971192","citation_count":54,"is_preprint":false},{"pmid":"18505570","id":"PMC_18505570","title":"Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18505570","citation_count":51,"is_preprint":false},{"pmid":"17785772","id":"PMC_17785772","title":"Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785772","citation_count":50,"is_preprint":false},{"pmid":"19888758","id":"PMC_19888758","title":"Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.","date":"2009","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19888758","citation_count":47,"is_preprint":false},{"pmid":"24886454","id":"PMC_24886454","title":"DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24886454","citation_count":44,"is_preprint":false},{"pmid":"17278098","id":"PMC_17278098","title":"BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17278098","citation_count":44,"is_preprint":false},{"pmid":"8519766","id":"PMC_8519766","title":"Transition state and rate-limiting step of the reaction catalyzed by the human dual-specificity phosphatase, VHR.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8519766","citation_count":43,"is_preprint":false},{"pmid":"25876765","id":"PMC_25876765","title":"DUSP3 Genetic Deletion Confers M2-like Macrophage-Dependent Tolerance to Septic Shock.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25876765","citation_count":41,"is_preprint":false},{"pmid":"25757426","id":"PMC_25757426","title":"VHR/DUSP3 phosphatase: structure, function and regulation.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25757426","citation_count":35,"is_preprint":false},{"pmid":"8755712","id":"PMC_8755712","title":"VHR and PTP1 protein phosphatases exhibit remarkably different active site specificities toward low molecular weight nonpeptidic substrates.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8755712","citation_count":35,"is_preprint":false},{"pmid":"12163160","id":"PMC_12163160","title":"4-isoavenaciolide covalently binds and inhibits VHR, a dual-specificity phosphatase.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12163160","citation_count":34,"is_preprint":false},{"pmid":"17012840","id":"PMC_17012840","title":"Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17012840","citation_count":33,"is_preprint":false},{"pmid":"24901344","id":"PMC_24901344","title":"Dusp3 and Psme3 are associated with murine susceptibility to Staphylococcus aureus infection and human sepsis.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24901344","citation_count":28,"is_preprint":false},{"pmid":"27941812","id":"PMC_27941812","title":"VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27941812","citation_count":25,"is_preprint":false},{"pmid":"28759036","id":"PMC_28759036","title":"Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28759036","citation_count":24,"is_preprint":false},{"pmid":"30069819","id":"PMC_30069819","title":"DUSP3/VHR: A Druggable Dual Phosphatase for Human Diseases.","date":"2019","source":"Reviews of physiology, biochemistry and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30069819","citation_count":22,"is_preprint":false},{"pmid":"17933004","id":"PMC_17933004","title":"Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects.","date":"2007","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/17933004","citation_count":22,"is_preprint":false},{"pmid":"24245651","id":"PMC_24245651","title":"Proteomic, cellular, and network analyses reveal new DUSP3 interactions with nucleolar proteins in HeLa cells.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/24245651","citation_count":20,"is_preprint":false},{"pmid":"29020102","id":"PMC_29020102","title":"Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29020102","citation_count":19,"is_preprint":false},{"pmid":"7775484","id":"PMC_7775484","title":"Human dual specificity phosphatase VHR activates maturation promotion factor and triggers meiotic maturation in Xenopus oocytes.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7775484","citation_count":19,"is_preprint":false},{"pmid":"30208163","id":"PMC_30208163","title":"Revisiting the roles of VHR/DUSP3 phosphatase in human diseases.","date":"2018","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/30208163","citation_count":15,"is_preprint":false},{"pmid":"18311544","id":"PMC_18311544","title":"High intracellular Zn2+ ions modulate the VHR, ZAP-70 and ERK activities of LNCaP prostate cancer cells.","date":"2008","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18311544","citation_count":15,"is_preprint":false},{"pmid":"32380926","id":"PMC_32380926","title":"DUSP3 maintains genomic stability and cell proliferation by modulating NER pathway and cell cycle regulatory proteins.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32380926","citation_count":14,"is_preprint":false},{"pmid":"15386195","id":"PMC_15386195","title":"A new VHR dual-specificity protein tyrosine phosphatase inhibitor from Dendrobium moniliforme.","date":"2004","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/15386195","citation_count":14,"is_preprint":false},{"pmid":"39103776","id":"PMC_39103776","title":"Gastric cancer cell-derived exosomal miR-541-5p induces M2 macrophage polarization through DUSP3/JAK2/STAT3 pathway.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39103776","citation_count":13,"is_preprint":false},{"pmid":"28389334","id":"PMC_28389334","title":"Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways.","date":"2017","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/28389334","citation_count":13,"is_preprint":false},{"pmid":"33777934","id":"PMC_33777934","title":"Nucleophosmin Protein Dephosphorylation by DUSP3 Is a Fine-Tuning Regulator of p53 Signaling to Maintain Genomic Stability.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33777934","citation_count":13,"is_preprint":false},{"pmid":"12494330","id":"PMC_12494330","title":"Inhibition of VHR dual-specificity protein tyrosine phosphatase activity by flavonoids isolated from Scutellaria baicalensis: structure-activity relationships.","date":"2002","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/12494330","citation_count":13,"is_preprint":false},{"pmid":"34704357","id":"PMC_34704357","title":"The genetic deletion of the Dual Specificity Phosphatase 3 (DUSP3) attenuates kidney damage and inflammation following ischaemia/reperfusion injury in mouse.","date":"2021","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34704357","citation_count":12,"is_preprint":false},{"pmid":"24798147","id":"PMC_24798147","title":"Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.","date":"2014","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24798147","citation_count":12,"is_preprint":false},{"pmid":"7829067","id":"PMC_7829067","title":"Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7829067","citation_count":11,"is_preprint":false},{"pmid":"38629726","id":"PMC_38629726","title":"Dehydroandrographolide facilitates M2 macrophage polarization by downregulating DUSP3 to inhibit sepsis-associated acute kidney injury.","date":"2024","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/38629726","citation_count":11,"is_preprint":false},{"pmid":"23322772","id":"PMC_23322772","title":"Specificity profiling of dual specificity phosphatase vaccinia VH1-related (VHR) reveals two distinct substrate binding modes.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23322772","citation_count":11,"is_preprint":false},{"pmid":"35705979","id":"PMC_35705979","title":"DUSP3 regulates phosphorylation-mediated degradation of occludin and is required for maintaining epithelial tight junction.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/35705979","citation_count":10,"is_preprint":false},{"pmid":"20215070","id":"PMC_20215070","title":"A context-sensitive technique robust to registration noise for change detection in VHR multispectral images.","date":"2010","source":"IEEE transactions on image processing : a publication of the IEEE Signal Processing Society","url":"https://pubmed.ncbi.nlm.nih.gov/20215070","citation_count":8,"is_preprint":false},{"pmid":"27423135","id":"PMC_27423135","title":"Reduced levels of Dusp3/Vhr phosphatase impair normal spindle bipolarity in an Erk1/2 activity-dependent manner.","date":"2016","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/27423135","citation_count":7,"is_preprint":false},{"pmid":"39959108","id":"PMC_39959108","title":"Fragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR (DUSP3) Phosphatase.","date":"2025","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/39959108","citation_count":7,"is_preprint":false},{"pmid":"37272465","id":"PMC_37272465","title":"Dual Specificity Phosphatase 3 (DUSP3) Knockdown Alleviates Acute Myocardial Infarction Damage via Inhibiting Apoptosis and Inflammation.","date":"2023","source":"Current neurovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37272465","citation_count":6,"is_preprint":false},{"pmid":"32348128","id":"PMC_32348128","title":"Allosteric Impact of the Variable Insert Loop in Vaccinia H1-Related (VHR) Phosphatase.","date":"2020","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32348128","citation_count":6,"is_preprint":false},{"pmid":"39083976","id":"PMC_39083976","title":"Exercise training-driven exosomal miRNA-323-5p activity suppresses adipogenic conversion of 3T3-L1 cells via the DUSP3/ERK pathway.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39083976","citation_count":5,"is_preprint":false},{"pmid":"24702858","id":"PMC_24702858","title":"RE12 derivatives displaying Vaccinia H1-related phosphatase (VHR) inhibition in the presence of detergent and their anti-proliferative activity against HeLa cells.","date":"2014","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24702858","citation_count":5,"is_preprint":false},{"pmid":"33479884","id":"PMC_33479884","title":"UV Radiation-induced Impairment of Cellular Morphology and Motility is Enhanced by DUSP3/VHR Loss and FAK Activation.","date":"2021","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33479884","citation_count":4,"is_preprint":false},{"pmid":"38367245","id":"PMC_38367245","title":"l-Methionine potentiates anticancer activity of Sorafenib by epigenetically altering DUSP3/ERK pathway in hepatocellular carcinoma.","date":"2024","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38367245","citation_count":4,"is_preprint":false},{"pmid":"39466786","id":"PMC_39466786","title":"The Dual-specificity Phosphatase 3 (DUSP3): A Potential Target Against Renal Ischemia/Reperfusion Injury.","date":"2024","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/39466786","citation_count":3,"is_preprint":false},{"pmid":"38538536","id":"PMC_38538536","title":"DUSP3 modulates IRES-dependent translation of mRNAs through dephosphorylation of the HNRNPC protein in cells under genotoxic stimulus.","date":"2024","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/38538536","citation_count":3,"is_preprint":false},{"pmid":"39744427","id":"PMC_39744427","title":"DUSP3 restrains the progression and stemness property of osteosarcoma through regulating EGFR/STAT3/SOX2 axis.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39744427","citation_count":2,"is_preprint":false},{"pmid":"41262879","id":"PMC_41262879","title":"BCL6, DUSP3, and IL6R Are Identified as Shared Druggable Immune-Regulatory Axis in Atrial Fibrillation and Atherosclerosis Through Integrative In Silico and In Vitro Analysis.","date":"2025","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/41262879","citation_count":1,"is_preprint":false},{"pmid":"39954561","id":"PMC_39954561","title":"Targeting DUSP3 promotes cell senescence by activating the notch1 pathway to treat hepatocellular carcinoma.","date":"2025","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/39954561","citation_count":1,"is_preprint":false},{"pmid":"39931530","id":"PMC_39931530","title":"USC-Derived Small Extracellular Vesicles-Functionalized Scaffolds Promote Scarless Vaginal Defect Repair via Delivery of Decorin and DUSP3 Proteins.","date":"2025","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39931530","citation_count":1,"is_preprint":false},{"pmid":"40392484","id":"PMC_40392484","title":"Overexpression of miR-20a targeting DUSP3 inhibits OCLN ubiquitination levels and alleviates sepsis induced intestinal barrier dysfunction.","date":"2025","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/40392484","citation_count":0,"is_preprint":false},{"pmid":"41287336","id":"PMC_41287336","title":"[Construction of etiological diagnosis model for pathogen-negative pulmonary tuberculosis using tuberculosis scores of GBP5, DUSP3, and TBP genes combined with inflammatory factors].","date":"2025","source":"Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","url":"https://pubmed.ncbi.nlm.nih.gov/41287336","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.30.615030","title":"Dual Specificity Phosphatase 3 knockdown drives myeloid leukemia cells to differentiate into macrophages and polarize","date":"2024-10-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.30.615030","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.08.617199","title":"Proteomic and transcriptomic host biomarkers for detection of pleural tuberculosis","date":"2024-10-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.08.617199","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33011,"output_tokens":7146,"usd":0.103111,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16309,"output_tokens":6001,"usd":0.115785,"stage2_stop_reason":"end_turn"},"total_usd":0.218896,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"Cys124 is the catalytic nucleophile of VHR/DUSP3: the C124S mutation abolishes both Tyr and Thr/Ser phosphatase activities, a thiol-phosphate enzyme intermediate forms at Cys124 during catalysis, and Cys124 is specifically alkylated by iodoacetate, establishing a mechanism identical to that of tyrosine-specific PTPs.\",\n      \"method\": \"Active-site mutagenesis (C124S), 32P-labeling of phosphoenzyme intermediate, iodoacetate alkylation, in vitro phosphatase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in vitro with mutagenesis and chemical modification, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"7961745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Pre-steady-state burst kinetics demonstrate that VHR/DUSP3 catalysis proceeds through a phosphoenzyme intermediate, and the rate-limiting step is decomposition of this intermediate (dephosphorylation), not the initial phosphoryl transfer from substrate to Cys124.\",\n      \"method\": \"Pre-steady-state burst kinetic analysis with p-nitrophenyl phosphate; linear free-energy relationship analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinetic reconstitution with rigorous mechanistic analysis\",\n      \"pmids\": [\"8519766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Crystal structure of VHR/DUSP3 at 2.1 Å resolution reveals a shallow active-site pocket (explaining dual-specificity toward pSer/pThr/pTyr) compared to the deeper pocket of tyrosine-specific PTPs, positively charged crevices near the active site, and a 'recognition region' (helix α1 to strand β1) that likely determines substrate specificity differences among DSPs and PTPs.\",\n      \"method\": \"X-ray crystallography at 2.1 Å resolution\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure, foundational structural study replicated and extended by subsequent work\",\n      \"pmids\": [\"8650541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Kinetic isotope effect measurements show VHR/DUSP3 employs a highly dissociative transition state for phosphoryl transfer (similar to uncatalyzed reaction and other PTPs), with Asp92 acting as general acid to protonate the leaving group; D92N mutant loses general acid assistance; S131A mutation raises the pKa of the nucleophilic Cys but does not alter transition-state structure.\",\n      \"method\": \"Kinetic isotope effects (18O nonbridge, 18O bridge, 15N) measured by isotope ratio mass spectrometry; site-directed mutagenesis (D92N, S131A, D92N/S131A)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous mechanistic in vitro study with multiple mutants and isotope effect measurements\",\n      \"pmids\": [\"8679534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERK1 and ERK2 are authentic substrates of VHR/DUSP3: VHR specifically dephosphorylates and inactivates ERK1/2 in vitro and in vivo (but not p38 or JNK in this study), with a second-order rate constant of ~40,000 M⁻¹s⁻¹; immunodepletion of endogenous VHR eliminates cellular ERK dephosphorylation; VHR is constitutively expressed and nuclear.\",\n      \"method\": \"Covalently immobilized mutant VHR affinity trap, kinetic in vitro phosphatase assay, transfection in COS-1 cells, immunodepletion\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate trap affinity enrichment + in vitro kinetics + cell-based immunodepletion, multiple orthogonal methods\",\n      \"pmids\": [\"10224087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Introduction of exogenous VHR into Jurkat T cells suppresses TCR-induced activation of ERK1/2 and JNK1/2 (and NFAT/AP-1 and Elk/c-Jun-driven reporters), but not p38 or NF-κB; catalytically inactive VHR mutants cause increased gene activation, indicating that endogenous VHR tonically suppresses the ERK and JNK pathways in T cells.\",\n      \"method\": \"Transfection of wild-type and catalytically inactive VHR in Jurkat T cells; luciferase reporter assays; kinase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function (dominant-negative) and gain-of-function with multiple pathway readouts replicated across reporters\",\n      \"pmids\": [\"11085983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Cu²⁺ ions potently and reversibly inactivate VHR/DUSP3 at submicromolar concentrations by oxidizing the active-site Cys124, as shown by loss of [¹⁴C]iodoacetate labeling of that residue; the reduction potential of VHR is estimated at −331 mV. Zn²⁺ inactivates VHR through a distinct mechanism not involving active-site Cys124.\",\n      \"method\": \"In vitro phosphatase activity assay with metal ions; [¹⁴C]iodoacetate active-site labeling; DTT reversal; Y78F mutant comparison\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro biochemical study with multiple methods but single lab, not independently replicated\",\n      \"pmids\": [\"11051099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structure at 2.75 Å of catalytically inactive C124S VHR in complex with a bisphosphorylated MAP kinase activation-loop peptide reveals that phosphotyrosine occupies the deep active-site cleft while phosphothreonine is tethered in a nearby basic pocket containing Arg158, explaining VHR's strong preference for dephosphorylating pTyr over pThr within bisphosphorylated -pTXpY- substrates.\",\n      \"method\": \"X-ray crystallography of C124S VHR–bisphosphorylated peptide complex at 2.75 Å; biochemical dephosphorylation assays; mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — first substrate-bound DSP crystal structure with biochemical validation of key residues\",\n      \"pmids\": [\"11863439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"VHR/DUSP3 efficiently dephosphorylates and inactivates JNK; the catalytically inactive C124S VHR forms a tight complex with activated JNK in vivo (substrate trap); c-Jun inhibits VHR-mediated JNK dephosphorylation in vitro by sterically blocking phosphorylation-site access when JNK and c-Jun are complexed, but c-Jun does not affect VHR activity toward ERK or artificial substrates.\",\n      \"method\": \"In vitro phosphatase assay, C124S substrate trap in vivo, c-Jun inhibition assay in vitro\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate trap plus in vitro kinetics plus mechanistic inhibition study, multiple methods in one lab\",\n      \"pmids\": [\"11971192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"VHR/DUSP3 is phosphorylated at Tyr138 by the ZAP-70 tyrosine kinase following TCR stimulation; Tyr138 phosphorylation is required for VHR to inhibit the ERK2-Elk-1 pathway, and the VHR(Y138F) mutant augments TCR-induced ERK2 activity and IL-2 gene activation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Y138F), transfection/reporter assay in T cells\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — writer kinase identified, phosphosite mutant with functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"12447358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RNAi-mediated loss of VHR/DUSP3 causes cell-cycle arrest at G1/S and G2/M transitions, senescence markers (β-galactosidase staining, autophagosomes, p21Cip/Waf1 upregulation, decreased telomerase), and hyperactivation of JNK and ERK; the cell-cycle arrest is reversed by JNK and ERK inhibition or knockdown, placing VHR upstream of these MAP kinases in cell-cycle regulation.\",\n      \"method\": \"RNAi knockdown, cell-cycle analysis, senescence assays (β-gal, autophagosome), kinase activity assays, JNK/ERK inhibitor rescue\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via inhibitor/siRNA rescue, multiple phenotypic readouts, replicated approach\",\n      \"pmids\": [\"16604064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VRK3 kinase binds directly to VHR/DUSP3 and enhances its phosphatase activity toward ERK in the nucleus through a mechanism independent of VRK3 kinase activity, thereby suppressing ERK signaling; VRK3 defines a class of 'phosphatase-activating kinases'.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase activity assay with VRK3, VRK3 kinase-dead mutant, nuclear co-localization studies\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding shown by Co-IP, activity enhancement confirmed in vitro with kinase-dead mutant ruling out indirect phosphorylation\",\n      \"pmids\": [\"16845380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"VHR/DUSP3 selectively dephosphorylates IFN-α/β-activated, tyrosine-phosphorylated STAT5 in the nucleus, inhibiting STAT5 transcriptional activity; Tyr138 phosphorylation of VHR is required for its phosphatase activity toward STAT5; the Src homology 2 (SH2) domain of STAT5 is required for effective dephosphorylation by VHR; Tyk2 kinase phosphorylates VHR at Tyr138.\",\n      \"method\": \"Phosphatase assay, co-immunoprecipitation, VHR Y138F mutant, STAT5 SH2-domain mutant analysis, reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — new substrate identified, phosphosite requirement established, reader domain requirement on substrate identified, writer kinase named, multiple orthogonal methods\",\n      \"pmids\": [\"17785772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VHR/DUSP3 localizes to the cytoplasm in primary keratinocytes but relocates to both cytoplasm and nucleus in cervical cancer cell lines; this relocalization correlates with post-translational stabilization of VHR protein (not increased DUSP3 transcription) in cancer cells.\",\n      \"method\": \"Immunofluorescence/confocal microscopy, Western blotting, RT-PCR\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment with functional implication (post-translational stabilization), two methods, single lab\",\n      \"pmids\": [\"18505570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GST-DUSP3 pulldown from HeLa cells exposed to gamma/UV radiation followed by LC-MS/MS identified Nucleophosmin (NPM), HnRNP C1/C2, and Nucleolin as direct DUSP3-interacting proteins; these interactions were validated by co-immunoprecipitation.\",\n      \"method\": \"GST pulldown, LC-MS/MS proteomics, co-immunoprecipitation validation\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pulldown with MS identification plus reciprocal Co-IP, single lab\",\n      \"pmids\": [\"24245651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Systematic combinatorial peptide library profiling reveals VHR/DUSP3 recognizes two distinct classes of phosphotyrosine peptide substrates: Class I ((D/E/ϕ)(D/S/N/T/E)(P/I/M/S/A/V)pY(G/A/S/Q)) binding in canonical orientation, and Class II ((V/A)P(I/L/M/V/F)Xn pY) binding in an inverted orientation where the N-terminus interacts with Asp164; this alternative binding mode was supported by site-directed mutagenesis and molecular modeling.\",\n      \"method\": \"Combinatorial peptide library screening, site-directed mutagenesis, molecular modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro substrate specificity reconstitution with mutagenesis, single lab but comprehensive systematic approach\",\n      \"pmids\": [\"23322772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VHR/DUSP3 can homodimerize inside cells; photo-cross-linking (pBPA amber suppression) and chemical cross-linkers identified Phe68 as a residue involved in dimerization; dimerization reduces VHR catalytic activity, suggesting the dimer interface occludes the active site as a negative regulatory mechanism.\",\n      \"method\": \"Unnatural amino acid (pBPA) photo-cross-linking, chemical cross-linking, in vitro phosphatase activity assay of dimeric vs monomeric VHR\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — novel method (amber suppression cross-linking) plus chemical cross-linking plus activity assay, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"24798147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DUSP3 deficiency in mice reduces neo-vascularization (b-FGF Matrigel plug, LLC tumor xenograft, aortic ring assay); DUSP3 knockdown in human endothelial cells reduces tube formation and spheroid sprouting, associated with increased PKC phosphorylation (not altered ERK1/2, JNK1/2, or EGFR phosphorylation in this context), identifying DUSP3 as a pro-angiogenic phosphatase.\",\n      \"method\": \"DUSP3-knockout mice (homologous recombination), RNAi in endothelial cells, Matrigel tube formation, aortic ring assay, phosphoprotein analysis\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mice plus in vitro RNAi with multiple angiogenesis assays, mechanistic link to PKC pathway identified\",\n      \"pmids\": [\"24886454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DUSP3 deficiency in mice promotes tolerance to LPS-induced endotoxin shock and polymicrobial septic shock; this is macrophage-dependent and transferable by adoptive transfer; DUSP3-/- mice show increased M2-like macrophages, decreased TNF production, and impaired ERK1/2 activation, demonstrating DUSP3 regulates innate immune responses through ERK1/2 and macrophage polarization.\",\n      \"method\": \"DUSP3-/- mice, LPS/CLP models, adoptive bone-marrow transfer, FACS macrophage phenotyping, ERK1/2 phosphorylation assay, ELISA for TNF\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with adoptive transfer (mechanistic proof of macrophage dependence), multiple readouts\",\n      \"pmids\": [\"25876765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Nuclear HSP70 enhances VHR/DUSP3 phosphatase activity via direct protein–protein interaction (not chaperone activity); VRK3 facilitates nuclear localization of HSP70; this VRK3/HSP70/VHR axis suppresses excessive ERK activation following glutamate excitotoxicity and reduces apoptosis and Aβ accumulation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase activity assay, nuclear localization signal-fused HSP70 overexpression, VRK3-deficient neurons, VRK3/HSP70 knockdown\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP binding plus direct phosphatase activity assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"27941812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of Dusp3/VHR by RNAi in human mitotic cancer cells causes multipolar spindle formation in an ERK1/2-dependent manner; normal bipolar spindle structure is restored by chemical inhibition of ERK1/2 or ectopic Dusp3 overexpression, placing Dusp3 upstream of ERK1/2 in mitotic spindle regulation.\",\n      \"method\": \"RNAi knockdown, ERK1/2 inhibitor rescue, Dusp3 overexpression rescue, spindle morphology analysis by microscopy\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis by inhibitor and overexpression rescue, single lab, clear phenotypic readout\",\n      \"pmids\": [\"27423135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VHR/DUSP3 directly dephosphorylates FAK (focal adhesion kinase) and paxillin in vitro; VHR overexpression decreases FAK tyrosine phosphorylation and VHR deficiency increases it; VHR-knockout cells show stronger FAK and paxillin phosphorylation, higher EGFR phosphorylation, long-lasting trailing ends, slower focal adhesion turnover, and elevated cell migration, identifying VHR as a FAK phosphatase regulating focal adhesion dynamics.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay with recombinant VHR and FAK, VHR-knockout mouse-derived cells, VHR overexpression, focal adhesion microscopy\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted phosphatase assay plus KO cells plus overexpression with multiple functional readouts, single lab but rigorous\",\n      \"pmids\": [\"28759036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Allosteric communication exists between the variable insert region (residue Asn74) and the catalytic acid loop of VHR/DUSP3: N74A mutation rigidifies the acid loop (NMR and MD simulations), disrupts active-site hydrogen bonds, weakens substrate affinity, and reduces substrate cleavage and hydrolysis rates >2-fold, despite the variable insert being ~20 Å from the active site.\",\n      \"method\": \"Solution NMR, molecular dynamics simulations, steady-state and rapid kinetic measurements, N74A site-directed mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR + computation + enzyme kinetics with mutagenesis in a single rigorous study, single lab\",\n      \"pmids\": [\"32348128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DUSP3 directly dephosphorylates Nucleophosmin (NPM) at tyrosines Y29, Y67, and Y271 after UV-radiation stress; DUSP3 knockdown causes early nucleolus exit of NPM and ARF, disruption of the HDM2-p53 interaction, increased p53-Ser15 phosphorylation, prolonged p53 half-life, and enhanced p53 transcriptional activity, demonstrating that DUSP3-mediated NPM dephosphorylation fine-tunes p53 signaling to maintain genomic stability.\",\n      \"method\": \"Co-immunoprecipitation, phospho-specific antibodies to individual NPM Tyr residues, in vitro phosphatase assay, DUSP3 siRNA knockdown, p53 stability/transcription assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct dephosphorylation assay plus site-specific phospho-antibodies plus KD with p53 pathway readouts, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"33777934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DUSP3 directly dephosphorylates occludin (OCLN) tyrosine residues; DUSP3 deficiency increases OCLN tyrosine phosphorylation, OCLN ubiquitination, and OCLN degradation, leading to disrupted tight junction ZO-1 distribution and impaired epithelial barrier function; DUSP3 also suppresses OCLN kinase FAK to reduce OCLN phosphorylation indirectly.\",\n      \"method\": \"Proximity ligation assay, immunoblotting, in vitro phosphatase assay, DUSP3-deficient cells, OCLN Tyr-to-Ala mutants, ubiquitination assay\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphatase reconstitution plus site-directed mutagenesis of substrate Tyr residues plus PLA and functional barrier assay, single lab\",\n      \"pmids\": [\"35705979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DUSP3 dephosphorylates HnRNP C (HNRNPC) tyrosine residues; DUSP3 knockdown causes tyrosine hyperphosphorylation of HNRNPC, increasing its RNA-binding ability and its association with IRES trans-acting factor (ITAF) complexes, leading to enhanced IRES-dependent translation of c-MYC and XIAP mRNAs. DUSP3 is present in 40S, monosome, and polysome fractions interacting with HNRNPC, PABP, and Nucleolin.\",\n      \"method\": \"DUSP3 siRNA knockdown, tyrosine phospho-HNRNPC immunoblotting, RNA immunoprecipitation, polysome fractionation, qPCR for mRNA levels vs protein levels\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple methods but single lab, no in vitro reconstitution of HNRNPC dephosphorylation by DUSP3\",\n      \"pmids\": [\"38538536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Fragment-based screening using fluorine NMR identified novel ligand-binding sites on VHR/DUSP3 distant from the conserved active site (allosteric sites); crystal structures confirmed fragment–protein interactions at these novel sites, providing structural basis for allosteric modulation.\",\n      \"method\": \"Fluorine NMR fragment screening, X-ray crystallography of fragment-bound VHR\",\n      \"journal\": \"ACS omega\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structures confirm binding sites but functional/activity consequences of allosteric site occupancy not fully characterized in abstracts reviewed\",\n      \"pmids\": [\"39959108\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DUSP3/VHR is a small, nuclear dual-specificity phosphatase that uses an active-site Cys124 thiol-phosphate intermediate (with Asp92 as general acid) to dephosphorylate phosphotyrosine preferentially within bisphosphorylated -pTXpY- motifs; its established substrates include ERK1/2, JNK1/2, STAT5 (after Tyk2-mediated VHR-pY138 activation), FAK, paxillin, nucleophosmin (Y29/Y67/Y271), occludin, and HnRNP C, placing DUSP3 as a constitutive brake on MAP kinase signaling that is itself regulated by ZAP-70/Tyk2-mediated Tyr138 phosphorylation, by VRK3-mediated allosteric activation (enhanced by nuclear HSP70), and by homodimerization-induced active-site occlusion; loss of DUSP3 causes G1/S and G2/M cell-cycle arrest, senescence, multipolar mitotic spindles, defective focal adhesion turnover, impaired angiogenesis, and altered innate immune macrophage polarization, while its nuclear dephosphorylation of NPM fine-tunes p53 stability and DNA-damage responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DUSP3 (VHR) is a constitutively expressed dual-specificity phosphatase that acts as a tonic brake on tyrosine-phosphorylation signaling, particularly within the MAP kinase pathways [#4, #5, #10]. Catalysis proceeds through a classical cysteine-based phosphatase mechanism: Cys124 is the nucleophile that forms a covalent thiol-phosphate intermediate, Asp92 serves as the general acid protonating the leaving group, and the rate-limiting step is decomposition of the phosphoenzyme intermediate via a highly dissociative transition state [#0, #1, #3]. A shallow active-site pocket accommodates pSer/pThr/pTyr, but structural and peptide-library analyses show a strong preference for dephosphorylating phosphotyrosine within bisphosphorylated -pTXpY- motifs, with phosphotyrosine occupying the deep catalytic cleft and phosphothreonine tethered in an adjacent basic pocket [#2, #7, #15]. Through this activity DUSP3 dephosphorylates and inactivates ERK1/2 and JNK1/2, and these substrates define its role in cell-cycle progression: loss of DUSP3 hyperactivates ERK and JNK, causing G1/S and G2/M arrest, senescence, and ERK-dependent multipolar mitotic spindles [#4, #8, #10, #20]. The enzyme is itself regulated on multiple axes — activating Tyr138 phosphorylation by ZAP-70 and Tyk2 (required for activity toward the ERK–Elk-1 pathway and STAT5) [#9, #12], allosteric activation by VRK3 binding that is enhanced by nuclear HSP70 [#11, #19], and negative regulation by homodimerization that occludes the active site [#16]. Beyond MAP kinases, DUSP3 dephosphorylates a defined set of substrates including STAT5 [#12], FAK and paxillin to control focal adhesion turnover and migration [#21], occludin to maintain tight-junction barrier integrity [#24], nucleophosmin (Y29/Y67/Y271) to fine-tune p53 stability and DNA-damage responses [#23], and HnRNP C to regulate IRES-dependent translation of c-MYC and XIAP [#25]. At the organismal level DUSP3 is pro-angiogenic [#17] and shapes innate immune responses, where its deficiency confers tolerance to endotoxin/septic shock through macrophage-dependent ERK1/2 regulation and M2 polarization [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established the catalytic mechanism of VHR/DUSP3 by identifying Cys124 as the nucleophile, resolving how a dual-specificity phosphatase achieves both pTyr and pSer/pThr hydrolysis.\",\n      \"evidence\": \"C124S mutagenesis, 32P phosphoenzyme intermediate trapping, iodoacetate alkylation, in vitro assay\",\n      \"pmids\": [\"7961745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological substrates\", \"Subcellular context and regulation unaddressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the kinetic pathway, showing the rate-limiting step is breakdown of the phosphoenzyme intermediate rather than initial phosphoryl transfer.\",\n      \"evidence\": \"Pre-steady-state burst kinetics with pNPP, linear free-energy analysis\",\n      \"pmids\": [\"8519766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Used artificial substrate only\", \"No physiological substrate kinetics\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Provided the structural basis for dual specificity and substrate recognition through the first crystal structure and transition-state/general-acid analysis.\",\n      \"evidence\": \"X-ray crystallography at 2.1 Å; kinetic isotope effects with D92N/S131A mutagenesis\",\n      \"pmids\": [\"8650541\", \"8679534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrate-bound complex\", \"Specificity determinants for cellular substrates not validated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified ERK1/2 as authentic cellular substrates, defining DUSP3 as a constitutive nuclear brake on MAP kinase signaling.\",\n      \"evidence\": \"Substrate-trap affinity enrichment, in vitro kinetics, immunodepletion in COS-1 cells\",\n      \"pmids\": [\"10224087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"JNK/p38 selectivity context-dependent\", \"Recruitment to substrates not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated DUSP3 tonically suppresses ERK and JNK in T cells, and that the active-site Cys is redox-sensitive, linking enzyme activity to signaling and metal-mediated regulation.\",\n      \"evidence\": \"WT/catalytically dead VHR in Jurkat cells with reporters; Cu2+/Zn2+ inactivation with iodoacetate labeling\",\n      \"pmids\": [\"11085983\", \"11051099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of metal inactivation in vivo unestablished\", \"p38/NF-κB exclusion may be cell-type specific\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved substrate recognition and activating regulation: a substrate-bound structure explained pTyr preference within -pTXpY- motifs, JNK was confirmed as substrate, and ZAP-70-mediated Tyr138 phosphorylation was shown to be required for activity.\",\n      \"evidence\": \"C124S–bisphosphopeptide crystal structure; JNK substrate trap with c-Jun inhibition; Co-IP/kinase assay/Y138F mutant in T cells\",\n      \"pmids\": [\"11863439\", \"11971192\", \"12447358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Tyr138-dependent activation not solved\", \"Whether c-Jun occlusion operates in vivo unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed DUSP3 upstream of ERK/JNK in cell-cycle control and identified VRK3 as a kinase-independent allosteric activator, revealing both phenotypic consequence and a novel activation mechanism.\",\n      \"evidence\": \"RNAi with senescence/cell-cycle assays and JNK/ERK inhibitor rescue; Co-IP and in vitro activity assay with VRK3 kinase-dead mutant\",\n      \"pmids\": [\"16604064\", \"16845380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of VRK3 allosteric activation undefined\", \"Direct cell-cycle substrate beyond ERK/JNK not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended substrate range to interferon-activated STAT5 and confirmed Tyk2-mediated Tyr138 phosphorylation as a requirement for activity, integrating DUSP3 into cytokine signaling.\",\n      \"evidence\": \"Phosphatase assay, Co-IP, VHR Y138F and STAT5 SH2-domain mutants, reporter assays\",\n      \"pmids\": [\"17785772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to IFN responses not tested\", \"Mechanism of SH2-dependent recognition not structurally defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked DUSP3 subcellular distribution to cancer, showing nuclear relocalization and post-translational stabilization in cervical cancer cells.\",\n      \"evidence\": \"Immunofluorescence, Western blot, RT-PCR in keratinocytes vs cancer lines\",\n      \"pmids\": [\"18505570\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of stabilization unknown\", \"Functional consequence of nuclear shift not directly tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the DNA-damage-induced interactome (NPM, HnRNP C1/C2, Nucleolin) and systematically mapped two substrate-peptide binding classes, broadening DUSP3 substrate logic beyond MAP kinases.\",\n      \"evidence\": \"GST pulldown with LC-MS/MS and Co-IP validation; combinatorial peptide library with mutagenesis and modeling\",\n      \"pmids\": [\"24245651\", \"23322772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pulldown interactions not yet shown to be catalytic substrates in 2013\", \"Class II inverted binding mode based partly on modeling\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Used knockout mice to establish DUSP3 as pro-angiogenic and to identify a PKC-linked, ERK-independent vascular function, demonstrating non-MAPK signaling roles in vivo.\",\n      \"evidence\": \"DUSP3-knockout mice, endothelial RNAi, Matrigel/aortic-ring/tube-formation assays, phosphoprotein analysis\",\n      \"pmids\": [\"24886454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PKC-pathway substrate not identified\", \"Mechanism connecting DUSP3 to angiogenesis incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed homodimerization as a negative autoregulatory mechanism that occludes the active site, adding a layer of intrinsic activity control.\",\n      \"evidence\": \"pBPA photo-cross-linking and chemical cross-linking identifying Phe68; activity assay of dimer vs monomer\",\n      \"pmids\": [\"24798147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular triggers governing monomer/dimer equilibrium unknown\", \"No structure of the dimer interface\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined DUSP3 as an innate-immune regulator, showing macrophage-dependent control of endotoxin/septic shock tolerance through ERK1/2 and M2 polarization.\",\n      \"evidence\": \"DUSP3-/- mice in LPS/CLP models, adoptive bone-marrow transfer, FACS, ERK1/2 and TNF readouts\",\n      \"pmids\": [\"25876765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct macrophage substrate beyond ERK pathway not pinned down\", \"Transcriptional drivers of M2 skewing unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected DUSP3 to mitotic fidelity and to a neuronal protective axis: ERK-dependent control of spindle bipolarity and HSP70-enhanced phosphatase activity downstream of VRK3.\",\n      \"evidence\": \"RNAi with ERK-inhibitor/overexpression rescue and spindle imaging; Co-IP, activity assay, NLS-HSP70 overexpression in neurons\",\n      \"pmids\": [\"27423135\", \"27941812\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HSP70 activation mechanism (non-chaperone) not structurally defined\", \"Spindle phenotype substrate(s) beyond ERK unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified FAK and paxillin as direct substrates, establishing DUSP3 control of focal adhesion turnover and cell migration.\",\n      \"evidence\": \"Co-IP, in vitro phosphatase assay with recombinant FAK, knockout cells, overexpression, focal adhesion microscopy\",\n      \"pmids\": [\"28759036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial regulation of cytoplasmic DUSP3 at adhesions not defined\", \"Interplay with EGFR signaling not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated long-range allosteric communication from the variable insert (Asn74) to the catalytic acid loop, revealing a structural route for activity modulation distant from the active site.\",\n      \"evidence\": \"Solution NMR, MD simulations, steady-state/rapid kinetics with N74A mutagenesis\",\n      \"pmids\": [\"32348128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ligand or modifier engaging this allosteric route unknown\", \"Link to VRK3/HSP70 activation not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed DUSP3 dephosphorylates NPM at three specific tyrosines to fine-tune p53 stability and the DNA-damage response, converting an earlier interactome hit into a defined catalytic substrate.\",\n      \"evidence\": \"Co-IP, site-specific phospho-antibodies, in vitro phosphatase assay, siRNA, p53 stability/transcription assays\",\n      \"pmids\": [\"33777934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NPM dephosphorylation requires VHR Tyr138 activation untested\", \"Nucleolar dynamics regulation mechanism incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified occludin as a direct substrate, linking DUSP3 to tight-junction stability and epithelial barrier function via both direct OCLN dephosphorylation and indirect FAK suppression.\",\n      \"evidence\": \"Proximity ligation assay, in vitro phosphatase assay, OCLN Tyr-to-Ala mutants, ubiquitination and barrier assays in deficient cells\",\n      \"pmids\": [\"35705979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo epithelial relevance not tested\", \"Which OCLN tyrosines are primary remains to be ranked\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended DUSP3 function to translational control, showing dephosphorylation of HnRNP C regulates IRES-dependent translation of c-MYC and XIAP and placing DUSP3 in ribosomal fractions.\",\n      \"evidence\": \"siRNA, phospho-HNRNPC immunoblot, RNA-IP, polysome fractionation, qPCR vs protein\",\n      \"pmids\": [\"38538536\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro reconstitution of HNRNPC dephosphorylation by DUSP3\", \"Direct vs indirect effect on translation not fully separated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mapped novel allosteric ligand-binding pockets distinct from the catalytic site, providing a structural foundation for allosteric modulators.\",\n      \"evidence\": \"Fluorine NMR fragment screening with X-ray crystallography of fragment-bound VHR\",\n      \"pmids\": [\"39959108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of occupying these sites not demonstrated\", \"No lead compound with cellular activity\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DUSP3's many regulatory inputs (Tyr138 phosphorylation, VRK3/HSP70 binding, dimerization, allosteric insert dynamics) are integrated to select among its diverse substrates in different compartments and cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of substrate selection\", \"Compartment-specific regulation incompletely mapped\", \"Disease-relevant substrate priorities not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 8, 12, 21, 23, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 10, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 11, 12, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13, 21]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 8, 12]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ERK1/2\", \"JNK\", \"STAT5\", \"VRK3\", \"FAK\", \"NPM1\", \"HNRNPC\", \"HSP70\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}